Novel combinations with oxaliplatin

ONCOLOGY

Volumn 14, Issue 12 SUPPL. 11, 2000, Pages 52-58

  Mani, Sridhar ^a   Manalo, Jane ^a   Bregman, David ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE; RALTITREXED; THIOPHENE DERIVATIVE;

CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; THIOPHENES;

EID: 84866835053     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Burchenal JH, Kalaher K, O'Toole T, et al: Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res 37:3455-3457, 1977.
2. Gibbons GR, Page JD, Mauldin SK, et al: Role of carrier ligand in platinum resistance in L1210 cells. Cancer Res 50:6497-6501, 1990.
3. Schmidt W. Chaney SG: Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799-805, 1993.
4. Vaisman A, Varchenko M, Umar A, et al: The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579-3585, 1998.
5. Jennerwein MM, Eastman A, Khokhar AR: Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. Chem Biol Interact 70:39-49, 1989.
6. Page JD, Husain I, Sancar A, et al: Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 29:1016-1024, 1990.
7. Noji M, Okamoto K, Kidani Y, et al: Relation of conformation to antitumor activity of platinum (II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl) cyclohexylamine isomers against leukemia P388. J Med Chem 24:508-515, 1981.
8. Zeghari-Squalli N, Misset JL, Cvitkovic E, et al: Mechanism of the in vitro synergism between SN38 and oxaliplatin (abstract). Proc Am Assoc Cancer Res 38:A20, 1997.
9. Zeghari-Squalli N, Raymond E, Cvitkovic E, et al: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 5:1189-1196, 1999.
10. Goldwasser F, Bozec L, Zeghari-Squalli N, et al: Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line. Anticancer Drugs 10:195-201, 1999.
11. Faivre S, Raymond E, Woynarowski JM, et al: Supra-additive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44:117-123, 1999.
12. Misset JL, Goldwasser F, Riofrio M, et al: Topotecan-oxaliplatin every 3 weeks: A phase I and pharmacologic study (abstract 845). Proc Am Soc Clin Oncol 18:220a, 1999.